Exchange: NASDAQ·Updated 05:51 AM EDT
ALT logo

ALTAltimmune Inc

$3.10
$0.0168
(0.54%)
Pre-Market
Prev Close $3.12
Reported EarningsAug 12
Mkt Cap$577.72M
Vol1,613.00

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
43

Bearish Sentiment

How do you feel about ALT?

Connect Stocktwits to ChatGPT

New

Real-time sentiment, trending & news in ChatGPT

  • Sentiment
  • Watchers
  • Trending
  • News
Connect Plugin

Advertisement|Remove ads.

Advertisement|Remove ads.